Letters: New Observations
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease†‡§
Funding agencies: This work was funded by the Reta Lila Weston Trust for Medical Research, and by a Medical Research Council (MRC) returning scientist, by the Wellcome Trust/MRC Parkinson's disease. This work was also supported by the National Institute for Health Research (NIHR)-funded University College London (UCL)/University College London Hospitals (UCLH) Comprehensive Biomedical Research Centre and by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC), whose members are from the UCL Institute of Neurology, the University of Sheffield, and the MRC Protein Phosphorylation Unit at the University of Dundee.
Relevant conflicts of interest/financial disclosures: J.H. is on Scientific Advisory Boards for Eisai and Merck Serono. A.L. is on Advisory Boards for Novartis. Teva, Meda, Boehringer Ingelheim, GSK, lpsen, Lundbeck, Allergan. Orion, BIAL, Noscira, and Roche.
Full financial disclosures and author roles may be found in the online version of this article.
No abstract is available for this article.